Download PDF
Thromb Haemost 2018; 118(07): 1257-1269
DOI: 10.1055/s-0038-1660437
New Technologies, Diagnostic Tools and Drugs
Georg Thieme Verlag KG Stuttgart · New York

Overcoming Heparin-Associated RT-qPCR Inhibition and Normalization Issues for microRNA Quantification in Patients with Acute Myocardial Infarction

Jose Coelho-Lima
1   Institute of Genetic Medicine, Newcastle University, International Centre for Life, Newcastle upon Tyne, United Kingdom
,
Ashfaq Mohammed
2   Department of Cardiology, Freeman Hospital, Newcastle upon Tyne NHS Foundation Trust, High Heaton, Newcastle upon Tyne, United Kingdom
,
Suzanne Cormack
2   Department of Cardiology, Freeman Hospital, Newcastle upon Tyne NHS Foundation Trust, High Heaton, Newcastle upon Tyne, United Kingdom
,
Samuel Jones
1   Institute of Genetic Medicine, Newcastle University, International Centre for Life, Newcastle upon Tyne, United Kingdom
,
Rajiv Das
2   Department of Cardiology, Freeman Hospital, Newcastle upon Tyne NHS Foundation Trust, High Heaton, Newcastle upon Tyne, United Kingdom
,
Mohaned Egred
2   Department of Cardiology, Freeman Hospital, Newcastle upon Tyne NHS Foundation Trust, High Heaton, Newcastle upon Tyne, United Kingdom
,
Pedram Panahi
2   Department of Cardiology, Freeman Hospital, Newcastle upon Tyne NHS Foundation Trust, High Heaton, Newcastle upon Tyne, United Kingdom
,
Simi Ali
3   Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
,
Ioakim Spyridopoulos
1   Institute of Genetic Medicine, Newcastle University, International Centre for Life, Newcastle upon Tyne, United Kingdom
2   Department of Cardiology, Freeman Hospital, Newcastle upon Tyne NHS Foundation Trust, High Heaton, Newcastle upon Tyne, United Kingdom
› Author Affiliations Funding Jose Coelho-Lima is supported by a CAPES Foundation PhD scholarship (Brazilian Ministry of Education; BEX 0881–14–7). Ioakim Spyridopoulos is supported by grants from the British Heart Foundation as well as the Newcastle Health Care Charity and the Newcastle upon Tyne Hospitals NHS Charity.
Further Information

Publication History

11 January 2018

02 May 2018

Publication Date:
11 June 2018 (online)

    Permissions and Reprints

Abstract

Background Cardiac-enriched micro ribonucleic acids (miRNAs) are released into the circulation following ST-elevation myocardial infarction (STEMI). Lack of standardized approaches for reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) data normalization and presence of RT-qPCR inhibitors (e.g. heparin) in patient blood samples have prevented reproducible miRNA quantification in this cohort and subsequent translation of these biomarkers to clinical practice.

Materials and Methods Using a RT-qPCR miRNA screening platform, we identified and validated an endogenous circulating miRNA as a normalization control. In addition, we assessed the effects of in vivo and in vitro anticoagulant drugs administration (heparin and bivalirudin) on three RT-qPCR normalization strategies (global miRNA mean, exogenous spike-in control [cel-miR-39] and endogenous miRNA control). Finally, we evaluated the effect of heparin and its in vitro inhibition with heparinase on the quantification of cardiac-enriched miRNAs in STEMI patients.

Results miR-425–5p was validated as an endogenous miRNA control. Heparin administration in vitro and in vivo inhibited all RT-qPCR normalization strategies. In contrast, bivalirudin had no effects on cel-miR-39 or miR-425–5p quantification. In vitro RNA sample treatment with 0.3 U of heparinase overcame heparin-induced over-estimation of cardiac-enriched miRNA levels and improved their correlation with high-sensitivity troponin T.

Conclusion miRNA quantification in STEMI patients receiving heparin is jeopardized by its effect on all RT-qPCR normalization approaches. Use of samples from bivalirudin-treated patients or in vitro treatment of heparin-contaminated samples with heparinase are suitable alternatives for miRNA quantification in this cohort. Finally, we reinforce the evidence that cardiac-enriched miRNAs early after myocardial reperfusion reflect the severity of cardiac injury.

Keywords

microRNA - RT-qPCR normalization - heparin - bivalirudin - myocardial infarction

Supplementary Material

 

  • References

  • 1 Steg PG, James SK, Atar D. , et al; Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33 (20) 2569-2619
    CrossrefPubMedGoogle Scholar
  • 2 van der Linden N, Streng AS, Bekers O, Wodzig WKWH, Meex SJR, de Boer D. Large variation in measured cardiac troponin T concentrations after standard addition in serum or plasma of different individuals. Clin Chem 2017; 63 (07) 1300-1302
    CrossrefPubMedGoogle Scholar
  • 3 Cobbaert CM, Bootsma M, Boden H. , et al. Confounding factors in the relation between high sensitivity cardiac troponin T levels in serum and infarct size of patients with first ST-elevation myocardial infarction. Int J Cardiol 2014; 172 (01) e3-e5
    CrossrefPubMedGoogle Scholar
  • 4 Mitchell PS, Parkin RK, Kroh EM. , et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008; 105 (30) 10513-10518
    CrossrefPubMedGoogle Scholar
  • 5 Chen X, Ba Y, Ma L. , et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18 (10) 997-1006
    CrossrefPubMedGoogle Scholar
  • 6 Weber JA, Baxter DH, Zhang S. , et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010; 56 (11) 1733-1741
    CrossrefPubMedGoogle Scholar
  • 7 Moldovan L, Batte KE, Trgovcich J, Wisler J, Marsh CB, Piper M. Methodological challenges in utilizing miRNAs as circulating biomarkers. J Cell Mol Med 2014; 18 (03) 371-390
    CrossrefPubMedGoogle Scholar
  • 8 Viereck J, Thum T. Circulating noncoding RNAs as biomarkers of cardiovascular disease and injury. Circ Res 2017; 120 (02) 381-399
    CrossrefPubMedGoogle Scholar
  • 9 Santovito D, Weber C. Zooming in on microRNAs for refining cardiovascular risk prediction in secondary prevention. Eur Heart J 2017; 38 (07) 524-528
    PubMedGoogle Scholar
  • 10 Marabita F, de Candia P, Torri A, Tegnér J, Abrignani S, Rossi RL. Normalization of circulating microRNA expression data obtained by quantitative real-time RT-PCR. Brief Bioinform 2016; 17 (02) 204-212
    CrossrefPubMedGoogle Scholar
  • 11 Boeckel JN, Thomé CE, Leistner D, Zeiher AM, Fichtlscherer S, Dimmeler S. Heparin selectively affects the quantification of microRNAs in human blood samples. Clin Chem 2013; 59 (07) 1125-1127
    CrossrefPubMedGoogle Scholar
  • 12 Kaudewitz D, Lee R, Willeit P. , et al. Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease. Thromb Haemost 2013; 110 (03) 609-615
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Li S, Zhang F, Cui Y. , et al. Modified high-throughput quantification of plasma microRNAs in heparinized patients with coronary artery disease using heparinase. Biochem Biophys Res Commun 2017; 493 (01) 556-561
    CrossrefPubMedGoogle Scholar
  • 14 Mestdagh P, Van Vlierberghe P, De Weer A. , et al. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol 2009; 10 (06) R64
    CrossrefPubMedGoogle Scholar
  • 15 Andersen CL, Jensen JL, Ørntoft TF. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 2004; 64 (15) 5245-5250
    CrossrefPubMedGoogle Scholar
  • 16 Vandesompele J, De Preter K, Pattyn F. , et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3 (07) H0034
    CrossrefPubMedGoogle Scholar
  • 17 Pfaffl MW, Tichopad A, Prgomet C, Neuvians TP. Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper--Excel-based tool using pair-wise correlations. Biotechnol Lett 2004; 26 (06) 509-515
    CrossrefPubMedGoogle Scholar
  • 18 Lippi G, Mattiuzzi C, Cervellin G. Circulating microRNAs (miRs) for diagnosing acute myocardial infarction: meta-analysis of available studies. Int J Cardiol 2013; 167 (01) 277-278
    CrossrefPubMedGoogle Scholar
  • 19 Ai J, Zhang R, Li Y. , et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun 2010; 391 (01) 73-77
    CrossrefPubMedGoogle Scholar
  • 20 Wang F, Long G, Zhao C. , et al. Plasma microRNA-133a is a new marker for both acute myocardial infarction and underlying coronary artery stenosis. J Transl Med 2013; 11: 222
    CrossrefPubMedGoogle Scholar
  • 21 Zhang L, Chen X, Su T. , et al. Circulating miR-499 are novel and sensitive biomarker of acute myocardial infarction. J Thorac Dis 2015; 7 (03) 303-308
    PubMedGoogle Scholar
  • 22 Zhang R, Lan C, Pei H, Duan G, Huang L, Li L. Expression of circulating miR-486 and miR-150 in patients with acute myocardial infarction. BMC Cardiovasc Disord 2015; 15: 51
    CrossrefPubMedGoogle Scholar
  • 23 Peng L, Chun-guang Q, Bei-fang L. , et al. Clinical impact of circulating miR-133, miR-1291 and miR-663b in plasma of patients with acute myocardial infarction. Diagn Pathol 2014; 9: 89
    CrossrefPubMedGoogle Scholar
  • 24 D'Alessandra Y, Devanna P, Limana F. , et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J 2010; 31 (22) 2765-2773
    CrossrefPubMedGoogle Scholar
  • 25 Olivieri F, Antonicelli R, Lorenzi M. , et al. Diagnostic potential of circulating miR-499-5p in elderly patients with acute non ST-elevation myocardial infarction. Int J Cardiol 2013; 167 (02) 531-536
    CrossrefPubMedGoogle Scholar
  • 26 Benz F, Roderburg C, Vargas Cardenas D. , et al. U6 is unsuitable for normalization of serum miRNA levels in patients with sepsis or liver fibrosis. Exp Mol Med 2013; 45: e42
    CrossrefPubMedGoogle Scholar
  • 27 McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras-Schimnich A. Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem 2011; 57 (06) 833-840
    CrossrefPubMedGoogle Scholar
  • 28 McDermott AM, Kerin MJ, Miller N. Identification and validation of miRNAs as endogenous controls for RQ-PCR in blood specimens for breast cancer studies. PLoS One 2013; 8 (12) e83718
    CrossrefPubMedGoogle Scholar
  • 29 Zhu M, Huang Z, Zhu D. , et al. A panel of microRNA signature in serum for colorectal cancer diagnosis. Oncotarget 2017; 8 (10) 17081-17091
    CrossrefPubMedGoogle Scholar
  • 30 Sun L, Jiang R, Li J. , et al. MicoRNA-425-5p is a potential prognostic biomarker for cervical cancer. Ann Clin Biochem 2017; 54 (01) 127-133
    CrossrefPubMedGoogle Scholar
  • 31 Di Pietro V, Ragusa M, Davies D. , et al. MicroRNAs as novel biomarkers for the diagnosis and prognosis of mild and severe traumatic brain injury. J Neurotrauma 2017; 34 (11) 1948-1956
    CrossrefPubMedGoogle Scholar
  • 32 Min PK, Kim JY, Chung KH. , et al. Local increase in microparticles from the aspirate of culprit coronary arteries in patients with ST-segment elevation myocardial infarction. Atherosclerosis 2013; 227 (02) 323-328
    CrossrefPubMedGoogle Scholar
  • 33 Dweep H, Gretz N. miRWalk2.0: a comprehensive atlas of microRNA-target interactions. Nat Methods 2015; 12 (08) 697
    CrossrefPubMedGoogle Scholar
  • 34 Panwar B, Omenn GS, Guan Y. miRmine: a database of human miRNA expression profiles. Bioinformatics 2017; 33 (10) 1554-1560
    PubMedGoogle Scholar
  • 35 Gidlöf O, van der Brug M, Ohman J. , et al. Platelets activated during myocardial infarction release functional miRNA, which can be taken up by endothelial cells and regulate ICAM1 expression. Blood 2013; 121 (19) 3908-3917 , S1–S26
    CrossrefPubMedGoogle Scholar
  • 36 Mitchell AJ, Gray WD, Hayek SS. , et al. Platelets confound the measurement of extracellular miRNA in archived plasma. Sci Rep 2016; 6: 32651
    CrossrefPubMedGoogle Scholar
  • 37 Satsangi J, Jewell DP, Welsh K, Bunce M, Bell JI. Effect of heparin on polymerase chain reaction. Lancet 1994; 343 (8911): 1509-1510
    PubMedGoogle Scholar
  • 38 Yokota M, Tatsumi N, Nathalang O, Yamada T, Tsuda I. Effects of heparin on polymerase chain reaction for blood white cells. J Clin Lab Anal 1999; 13 (03) 133-140
    CrossrefPubMedGoogle Scholar
  • 39 Turchinovich A, Burwinkel B. Distinct AGO1 and AGO2 associated miRNA profiles in human cells and blood plasma. RNA Biol 2012; 9 (08) 1066-1075
    CrossrefPubMedGoogle Scholar
  • 40 Johnson ML, Navanukraw C, Grazul-Bilska AT, Reynolds LP, Redmer DA. Heparinase treatment of RNA before quantitative real-time RT-PCR. Biotechniques 2003; 35 (06) 1140-1142 , 1144
    CrossrefPubMedGoogle Scholar
  • 41 Plieskatt JL, Feng Y, Rinaldi G, Mulvenna JP, Bethony JM, Brindley PJ. Circumventing qPCR inhibition to amplify miRNAs in plasma. Biomark Res 2014; 2: 13
    CrossrefPubMedGoogle Scholar
  • 42 Ibanez B, James S, Agewall S. , et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39 (02) 119-177
    CrossrefPubMedGoogle Scholar
  • 43 Gidlöf O, Andersson P, van der Pals J, Götberg M, Erlinge D. Cardiospecific microRNA plasma levels correlate with troponin and cardiac function in patients with ST elevation myocardial infarction, are selectively dependent on renal elimination, and can be detected in urine samples. Cardiology 2011; 118 (04) 217-226
    CrossrefPubMedGoogle Scholar
  • 44 Bauters C, Kumarswamy R, Holzmann A. , et al. Circulating miR-133a and miR-423-5p fail as biomarkers for left ventricular remodeling after myocardial infarction. Int J Cardiol 2013; 168 (03) 1837-1840
    CrossrefPubMedGoogle Scholar
  • 45 Białek S, Górko D, Zajkowska A. , et al. Release kinetics of circulating miRNA-208a in the early phase of myocardial infarction. Kardiol Pol 2015; 73 (08) 613-619
    CrossrefPubMedGoogle Scholar